This is a multicenter, open-label, Phase 1a/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of luxeptinib (CG-806) in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or non-Hodgkin's lymphoma patients. This is to be followed by a cohort expansion phase at the MTD or recommended dose.
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Aptose Biosciences Inc.
The following cities have luxeptinib (CG-806) clinical trial sites. Please check back often as locations will be updated.
For more information on enrollment in our current clinical trials, please contact us or visit clinicaltrials.gov for location information.
The safety and efficacy of the investigational use of these products have not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.